{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:59:46Z","timestamp":1792094386053,"version":"4.4.0"},"reference-count":99,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The serine\/threonine kinase mechanistic target of rapamycin (mTOR) plays a pivotal role in the regulation of cell proliferation, survival, and motility in response to availability of energy and nutrients as well as mitogens. The mTOR signaling axis regulates important biological processes, including cellular growth, metabolism, and survival in many tissues. In the skin, dysregulation of PI3K\/AKT\/mTOR pathway may lead to severe pathological conditions characterized by uncontrolled proliferation and inflammation, including skin hyperproliferative as well as malignant diseases. Herein, we provide an update on the current knowledge regarding the pathogenic implication of the mTOR pathway in skin diseases with inflammatory features (such as psoriasis, atopic dermatitis, pemphigus, and acne) and malignant characteristics (such as cutaneous T cell lymphoma and melanoma) while we critically discuss current and future perspectives for therapeutic targeting of mTOR axis in clinical practice.<\/jats:p>","DOI":"10.3390\/ijms23031693","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:59:21Z","timestamp":1643709561000},"page":"1693","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Predominant Role of mTOR Signaling in Skin Diseases with Therapeutic Potential"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-2199","authenticated-orcid":false,"given":"Fani","family":"Karagianni","sequence":"first","affiliation":[{"name":"National Center of Rare Diseases\u2014Cutaneous Lymphoma, Second Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5689-1795","authenticated-orcid":false,"given":"Antreas","family":"Pavlidis","sequence":"additional","affiliation":[{"name":"National Center of Rare Diseases\u2014Cutaneous Lymphoma, Second Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina S.","family":"Malakou","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-0618","authenticated-orcid":false,"given":"Christina","family":"Piperi","sequence":"additional","affiliation":[{"name":"Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[{"name":"National Center of Rare Diseases\u2014Cutaneous Lymphoma, Second Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"ref_1","unstructured":"(2021, December 14). Alcalay Joseph Dermatology: A Medical, Surgical and Aesthetic Profession\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/18669131\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11845-016-1424-8","article-title":"An Analysis of inpatient dermatologic consultations at University Hospital Limerick: Inadequate infrastructure leads to acute skin failure","volume":"186","author":"Alani","year":"2017","journal-title":"Iran. J. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000136656","article-title":"Prevalence of skin diseases in a cohort of 48,665 employees in Germany","volume":"217","author":"Schaefer","year":"2008","journal-title":"Dermatology"},{"key":"ref_5","unstructured":"Bolognia, J.L., Schaffer, J.L., and Cerroni, L. (2021, December 14). Dermatology: 2-Volume Set\u20149780702062759. Available online: https:\/\/www.us.elsevierhealth.com\/dermatology-2-volume-set-9780702062759.html."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.jid.2020.03.969","article-title":"The Skin Science Foundation: Promoting skin health through research","volume":"140","author":"Gilliet","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ding, X., Bloch, W., Iden, S., R\u00fcegg, M.A., Hall, M.N., Leptin, M., Partridge, L., and Eming, S.A. (2016). MTORC1 and MTORC2 regulate skin morphogenesis and epidermal barrier formation. Nat. Commun., 7.","DOI":"10.1038\/ncomms13226"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Madonna, S., Scarponi, C., Pallotta, S., Cavani, A., and Albanesi, C. (2012). Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis. Cell Death Dis., 3.","DOI":"10.1038\/cddis.2012.69"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32856","DOI":"10.1074\/jbc.M506119200","article-title":"Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death","volume":"280","author":"Calautti","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.270.5233.50","article-title":"PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints","volume":"270","author":"Keith","year":"1995","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"MTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","article-title":"GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and MTOR","volume":"11","author":"Kim","year":"2003","journal-title":"Mol. Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","article-title":"Ablation in mice of the MTORC components raptor, rictor, or MLST8 reveals that MTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1","volume":"11","author":"Guertin","year":"2006","journal-title":"Dev. Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/9780470559277.ch110042","article-title":"Chemical synthesis of hydrocarbon-stapled peptides for protein interaction research and therapeutic targeting","volume":"3","author":"Bird","year":"2011","journal-title":"Curr. Protoc. Chem. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15461","DOI":"10.1074\/jbc.C200665200","article-title":"The mammalian target of rapamycin (MTOR) partner, raptor, binds the MTOR substrates P70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif","volume":"278","author":"Nojima","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an MTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the MTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-MTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Huang, S. (2020). MTOR signaling in metabolism and cancer. Cells, 9.","DOI":"10.3390\/cells9102278"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes Dev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","article-title":"MTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events","volume":"123","author":"Holz","year":"2005","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1126\/science.1130276","article-title":"S6K1- and BetaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth","volume":"314","author":"Dorrello","year":"2006","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8862","DOI":"10.1128\/MCB.23.23.8862-8877.2003","article-title":"MTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF","volume":"23","author":"Hannan","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.cell.2011.06.034","article-title":"MTOR complex 1 regulates lipin 1 localization to control the SREBP pathway","volume":"146","author":"Peterson","year":"2011","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.2337\/diabetes.53.11.2748","article-title":"Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis","volume":"53","author":"Kim","year":"2004","journal-title":"Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.aad0489","article-title":"mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle","volume":"351","author":"Hoxhaj","year":"2016","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through MTOR and S6K1","volume":"339","author":"Howell","year":"2013","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fcell.2019.00192","article-title":"Pleiotropic effects of mTOR and autophagy during development and aging","volume":"7","author":"Schmeisser","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cellsig.2005.07.010","article-title":"Protein kinase C and the regulation of the actin cytoskeleton","volume":"18","author":"Larsson","year":"2006","journal-title":"Cell. Signal."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.neo.2018.10.001","article-title":"Inhibition of MTORC2\/RICTOR impairs melanoma hepatic metastasis","volume":"20","author":"Schmidt","year":"2018","journal-title":"Neoplasia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.cmet.2013.04.010","article-title":"Dynamic adipocyte phosphoproteome reveals that Akt directly regulates MTORC2","volume":"17","author":"Humphrey","year":"2013","journal-title":"Cell Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses MTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Buerger, C., Shirsath, N., Lang, V., Berard, A., Diehl, S., Kaufmann, R., Boehncke, W.H., and Wolf, P. (2017). Inflammation dependent MTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180853"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tang, Z.L., Zhang, K., Lv, S.C., Xu, G.W., Zhang, J.F., and Jia, H.Y. (2021). LncRNA MEG3 suppresses PI3K\/AKT\/mTOR signalling pathway to enhance autophagy and inhibit inflammation in TNF-\u03b1-treated keratinocytes and psoriatic mice. Cytokine, 148.","DOI":"10.1016\/j.cyto.2021.155657"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopha.2017.03.105","article-title":"MiR-155 promotes cell proliferation and inhibits apoptosis by PTEN signaling pathway in the psoriasis","volume":"90","author":"Xu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.biopha.2018.04.145","article-title":"MiR-876-5p suppresses cell proliferation by targeting Angiopoietin-1 in the psoriasis","volume":"103","author":"A","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1016\/j.bbadis.2018.07.036","article-title":"Polycystin-1 downregulation induces ERK-dependent MTOR pathway activation in a cellular model of psoriasis","volume":"1864","author":"Gargalionis","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/jid.2013.3","article-title":"1\u03b1,25-Dihydroxyvitamin-D3-3-Bromoacetate regulates AKT\/MTOR signaling cascades: A therapeutic agent for psoriasis","volume":"133","author":"Raychaudhuri","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1136\/ard.2008.098459","article-title":"The PI3K\/Akt\/MTOR pathway in innate immune cells: Emerging therapeutic applications","volume":"67","author":"Weichhart","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2340\/00015555-1737","article-title":"Phosphoinositide-3 kinase\/protein kinase-B\/mammalian target of rapamycin pathway in psoriasis pathogenesis. A potential therapeutic target?","volume":"94","author":"Huang","year":"2014","journal-title":"Acta Derm.-Venereol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.47.120505.105359","article-title":"MTOR pathway as a target in tissue hypertrophy","volume":"47","author":"Lee","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/exd.13461","article-title":"TNF stimulates IL-6, CXCL8 and VEGF secretion from human keratinocytes via activation of MTOR, inhibited by tetramethoxyluteolin","volume":"27","author":"Patel","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbadis.2018.02.003","article-title":"PI3K\/AKT\/MTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis","volume":"1864","author":"Varshney","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jid.2016.03.016","article-title":"Constitutive autophagy and nucleophagy during epidermal differentiation","volume":"136","author":"Akinduro","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/MMBR.69.1.79-100.2005","article-title":"Signaling by target of rapamycin proteins in cell growth control","volume":"69","author":"Inoki","year":"2005","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3389\/fimmu.2018.02786","article-title":"Epidermal MTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target","volume":"9","author":"Buerger","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2012.06.316","article-title":"IL-22 induced cell proliferation is regulated by PI3K\/Akt\/MTOR signaling cascade","volume":"60","author":"Mitra","year":"2012","journal-title":"Cytokine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/1523-1747.ep12696808","article-title":"Increased phosphatidylinositol kinase activity in psoriatic epidermis","volume":"92","author":"Pike","year":"1989","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cellimm.2009.03.020","article-title":"The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn\u2019s disease","volume":"258","author":"Ochaion","year":"2009","journal-title":"Cell. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ainali, C., Valeyev, N., Perera, G., Williams, A., Gudjonsson, J.E., Ouzounis, C.A., Nestle, F.O., and Tsoka, S. (2012). Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genom., 13.","DOI":"10.1186\/1471-2164-13-472"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/bjd.12271","article-title":"Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin","volume":"169","author":"Buerger","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/exd.12779","article-title":"8-Methoxypsoralen plus UVA (PUVA) therapy normalizes signalling of phosphorylated component of MTOR pathway in psoriatic skin of K5. HTGF\u03b21 transgenic mice","volume":"24","author":"Shirsath","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.molmed.2020.04.004","article-title":"Metabolic pathways that control skin homeostasis and inflammation","volume":"26","author":"Cibrian","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.7150\/ijms.45765","article-title":"Rapamycin blocks the IL-13-induced deficiency of epidermal barrier related proteins via upregulation of MiR-143 in HaCaT keratinocytes","volume":"17","author":"Jia","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3389\/fimmu.2020.00752","article-title":"IL-37 ameliorating allergic inflammation in atopic dermatitis through regulating microbiota and AMPK-MTOR signaling pathway-modulated autophagy mechanism","volume":"11","author":"Hou","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2006.04.042","article-title":"New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions","volume":"118","author":"Cork","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jaci.2016.09.052","article-title":"A mechanistic target of rapamycin complex 1\/2 (MTORC1)\/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)\/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis","volume":"139","author":"Naeem","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fmed.2018.00226","article-title":"The genetics of pemphigus vulgaris","volume":"5","author":"Vodo","year":"2018","journal-title":"Front. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3389\/fimmu.2019.01391","article-title":"Identification of a novel non-desmoglein autoantigen in pemphigus vulgaris","volume":"10","author":"Calabresi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1152\/ajpcell.00161.2008","article-title":"Apoptosis is not required for acantholysis in pemphigus vulgaris","volume":"296","author":"Schmidt","year":"2009","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1600-0625.2009.00934.x","article-title":"Apoptolysis: A novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis","volume":"18","author":"Grando","year":"2009","journal-title":"Exp. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/abbs\/gmab008","article-title":"MTOR pathway regulates the differentiation of peripheral blood Th2\/Treg cell subsets in patients with pemphigus vulgaris","volume":"53","author":"Lai","year":"2021","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Fabbrocini, G., Annunziata, M.C., D\u2019Arco, V., de Vita, V., Lodi, G., Mauriello, M.C., Pastore, F., and Monfrecola, G. (2010). Acne scars: Pathogenesis, classification and treatment. Dermatol. Res. Pract., 2010.","DOI":"10.1155\/2010\/893080"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.pdpdt.2017.03.006","article-title":"ALA-PDT suppressing the cell growth and reducing the lipogenesis in human SZ95 sebocytes by MTOR signaling pathway in vitro","volume":"18","author":"Tuo","year":"2017","journal-title":"Photodiagn. Photodyn. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/exd.12885","article-title":"Mechanistic target of rapamycin (MTOR) expression is increased in acne patients\u2019 skin","volume":"25","author":"Monfrecola","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.14409","article-title":"Skin expression of mammalian target of rapamycin and forkhead box transcription factor O1, and serum insulin-like growth factor-1 in patients with acne vulgaris and their relationship with diet","volume":"174","author":"Agamia","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1365-2133.2010.09754.x","article-title":"Is nuclear deficiency of FoxO1 due to increased growth factor\/PI3K\/Akt-signalling in acne vulgaris reversed by isotretinoin treatment?","volume":"162","author":"Melnik","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4161\/derm.15331","article-title":"Isotretinoin and FoxO1: A scientific hypothesis","volume":"3","author":"Melnik","year":"2011","journal-title":"Dermato-Endocrinology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/exd.12172","article-title":"Are Therapeutic effects of antiacne agents mediated by activation of FoxO1 and inhibition of MTORC1?","volume":"22","author":"Melnik","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12967-017-1297-2","article-title":"P53: Key conductor of all anti-acne therapies","volume":"15","author":"Melnik","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bjd.16231","article-title":"Acne and hidradenitis suppurativa","volume":"178","author":"Pink","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/1744666X.2021.1919085","article-title":"Novel therapeutic approaches for cutaneous T cell lymphomas","volume":"17","author":"Pavlidis","year":"2021","journal-title":"Exp. Rev. Clin. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1600-0625.2010.01102.x","article-title":"Cutaneous T-cell lymphoma cells are sensitive to rapamycin","volume":"19","author":"Kremer","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.leu.2404350","article-title":"Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma","volume":"20","author":"Krejsgaard","year":"2006","journal-title":"Leukemia"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/jid.2015.153","article-title":"Rapamycin suppresses tumor growth and alters the metabolic phenotype in T-cell lymphoma","volume":"135","author":"Kittipongdaja","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00403-019-02000-0","article-title":"Molecular profiling of TOX-deficient neoplastic cells in cutaneous T cell lymphoma","volume":"312","author":"Xu","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2006.06.0442","article-title":"Toward a molecular classification of melanoma","volume":"25","author":"Fecher","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5590","DOI":"10.1038\/s41388-021-01911-5","article-title":"Targeting MTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11523-018-0565-2","article-title":"The role of autophagy in the resistance to BRAF inhibition in BRAF-mutated melanoma","volume":"13","author":"Liu","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Shao, Z., Bao, Q., Jiang, F., Qian, H., Fang, Q., and Hu, X. (2015). VS-5584, a novel PI3K-MTOR dual inhibitor, inhibits melanoma cell growth in vitro and in vivo. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132655"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1440-0960.2011.00837.x","article-title":"Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: A pilot study of four patients","volume":"53","author":"Foster","year":"2012","journal-title":"Australas. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2133.2005.06438.x","article-title":"Treatment of psoriasis with topical sirolimus: Preclinical development and a randomized, double-blind trial","volume":"152","author":"Ormerod","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2133.2006.07602.x","article-title":"Severe psoriasis treated with a new macrolide: Everolimus","volume":"156","author":"Frigerio","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1365-2133.2001.04376.x","article-title":"Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial","volume":"145","author":"Reitamo","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/dth.12176","article-title":"Combination of everolimus and tacrolimus: A potentially effective regimen for recalcitrant psoriasis","volume":"28","author":"Wei","year":"2015","journal-title":"Dermatol. Ther."},{"key":"ref_88","first-page":"854","article-title":"Upregulation of PI3K\/AKT\/MTOR, FABP5 and PPAR\u03b2\/\u03b4 in human psoriasis and imiquimod-induced murine psoriasiform dermatitis model","volume":"96","author":"Chamcheu","year":"2016","journal-title":"Acta Derm.-Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2340\/00015555-2724","article-title":"Blocking MTOR signalling with rapamycin ameliorates imiquimod-induced psoriasis in mice","volume":"97","author":"Buerger","year":"2017","journal-title":"Acta Derm.-Venereol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/exd.13745","article-title":"Rapamycin ameliorates psoriasis by regulating the expression and methylation levels of tropomyosin via ERK1\/2 and MTOR pathways in vitro and in vivo","volume":"27","author":"Gao","year":"2018","journal-title":"Exp. Dermatol."},{"key":"ref_91","first-page":"8","article-title":"Current development of the second generation of MTOR inhibitors as anticancer agents","volume":"31","author":"Zhou","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.2174\/138161212800626210","article-title":"Targeting MTOR pathways in human malignancies","volume":"18","author":"Fasolo","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bcp.12888","article-title":"Targeting MTOR for the treatment of B cell malignancies","volume":"82","author":"Lee","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jid.2019.08.454","article-title":"Preclinical evidence for targeting PI3K\/MTOR signaling with dual-inhibitors as a therapeutic strategy against cutaneous T-cell lymphoma","volume":"140","author":"Bresin","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-3-39","article-title":"Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and MTOR inhibitor rapamycin","volume":"3","author":"Molhoek","year":"2005","journal-title":"J. Transl. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jaad.2018.10.070","article-title":"Topical use of mammalian target of rapamycin inhibitors in dermatology: A systematic review with meta-analysis","volume":"80","author":"Leducq","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-11-0989","article-title":"Combinations of BRAF, MEK, and PI3K\/MTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations","volume":"11","author":"Greger","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Xie, X., White, E.P., and Mehnert, J.M. (2013). Coordinate autophagy and MTOR pathway inhibition enhances cell death in melanoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055096"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2017.07.021","article-title":"Synergistic anti-tumor effect of 17AAG with the PI3K\/MTOR inhibitor NVP-BEZ235 on human melanoma","volume":"406","author":"Calero","year":"2017","journal-title":"Cancer Lett."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1693\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:12:31Z","timestamp":1760134351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23031693"],"URL":"https:\/\/doi.org\/10.3390\/ijms23031693","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}